SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Syros Pharmaceuticals, Inc. (SYRS) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+4762757.1%).
- Analyst consensus target $16.67 (+4762757.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 35/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SYRS
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-5.81
Book Value / Share$0.00
Revenue / Share$0.35
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$16.67 (+4762757.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-54.25 |
$0.00 |
$-13.43M |
- |
| 2015 |
$-120.45 |
$317K |
$-29.82M |
-9406.3% |
| 2016 |
$-37.60 |
$317K |
$-47.74M |
-15060.9% |
| 2017 |
$-21.26 |
$1.1M |
$-54.01M |
-4905.5% |
| 2018 |
$-19.07 |
$2.05M |
$-62.28M |
-3038% |
| 2019 |
$-18.76 |
$1.98M |
$-75.44M |
-3806.2% |
| 2020 |
$-18.64 |
$15.09M |
$-85.83M |
-568.7% |
| 2021 |
$-14.47 |
$23.49M |
$-90.47M |
-385.2% |
| 2022 |
$-3.90 |
$14.88M |
$-49.3M |
-331.3% |
| 2023 |
$-5.81 |
$9.94M |
$-164.57M |
-1656.3% |
